Logo image of FOLD

AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis

NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD

9.19  +0.12 (+1.32%)

After market: 9.19 0 (0%)

Fundamental Rating

4

FOLD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. FOLD has a medium profitability rating, but doesn't score so well on its financial health evaluation. FOLD is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year FOLD has reported negative net income.
FOLD had a negative operating cash flow in the past year.
FOLD had negative earnings in each of the past 5 years.
In the past 5 years FOLD always reported negative operating cash flow.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.15%, FOLD belongs to the top of the industry, outperforming 88.63% of the companies in the same industry.
FOLD's Return On Equity of -28.91% is fine compared to the rest of the industry. FOLD outperforms 79.57% of its industry peers.
FOLD has a better Return On Invested Capital (4.23%) than 94.32% of its industry peers.
Industry RankSector Rank
ROA -7.15%
ROE -28.91%
ROIC 4.23%
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

FOLD has a better Operating Margin (6.45%) than 94.67% of its industry peers.
FOLD has a Gross Margin of 89.98%. This is amongst the best in the industry. FOLD outperforms 93.25% of its industry peers.
FOLD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.45%
PM (TTM) N/A
GM 89.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.
The number of shares outstanding for FOLD has been increased compared to 1 year ago.
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
FOLD has a better debt/assets ratio than last year.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.74, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.74, FOLD is in line with its industry, outperforming 59.86% of the companies in the same industry.
A Debt/Equity ratio of 2.01 is on the high side and indicates that FOLD has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.01, FOLD is doing worse than 82.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.01
Debt/FCF N/A
Altman-Z -0.74
ROIC/WACC0.44
WACC9.67%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.39 indicates that FOLD has no problem at all paying its short term obligations.
FOLD's Current ratio of 3.39 is in line compared to the rest of the industry. FOLD outperforms 40.14% of its industry peers.
A Quick Ratio of 2.60 indicates that FOLD has no problem at all paying its short term obligations.
The Quick ratio of FOLD (2.60) is worse than 69.45% of its industry peers.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 2.6
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.55%, which is quite impressive.
The Revenue has grown by 32.28% in the past year. This is a very strong growth!
FOLD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.73% yearly.
EPS 1Y (TTM)72.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%181.82%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%30.09%

3.2 Future

The Earnings Per Share is expected to grow by 85.87% on average over the next years. This is a very strong growth
FOLD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.95% yearly.
EPS Next Y183.38%
EPS Next 2Y127.63%
EPS Next 3Y114.67%
EPS Next 5Y85.87%
Revenue Next Year20.92%
Revenue Next 2Y21.85%
Revenue Next 3Y22.2%
Revenue Next 5Y20.95%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 78.73.
91.12% of the companies in the same industry are more expensive than FOLD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of FOLD to the average of the S&P500 Index (22.70), we can say FOLD is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 78.73
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

93.78% of the companies in the same industry are more expensive than FOLD, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 66.88
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FOLD's earnings are expected to grow with 114.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y127.63%
EPS Next 3Y114.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FOLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (2/21/2025, 8:20:09 PM)

After market: 9.19 0 (0%)

9.19

+0.12 (+1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners94.04%
Inst Owner Change-90.8%
Ins Owners0.7%
Ins Owner Change13.03%
Market Cap2.75B
Analysts82.22
Price Target17.43 (89.66%)
Short Float %6.48%
Short Ratio7.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-0.83%
Max Revenue beat(2)2.52%
Revenue beat(4)2
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-2.65%
Max Revenue beat(4)2.52%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)7
Avg Revenue beat(12)-0.63%
Revenue beat(16)8
Avg Revenue beat(16)-1.2%
PT rev (1m)-1.4%
PT rev (3m)-2.08%
EPS NQ rev (1m)-549.3%
EPS NQ rev (3m)-223.8%
EPS NY rev (1m)-21.62%
EPS NY rev (3m)-40.46%
Revenue NQ rev (1m)-1.56%
Revenue NQ rev (3m)-3.36%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 78.73
P/S 5.2
P/FCF N/A
P/OCF N/A
P/B 14.15
P/tB N/A
EV/EBITDA 66.88
EPS(TTM)-0.14
EYN/A
EPS(NY)0.12
Fwd EY1.27%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS1.77
BVpS0.65
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.15%
ROE -28.91%
ROCE 5.35%
ROIC 4.23%
ROICexc 6.96%
ROICexgc 15.7%
OM 6.45%
PM (TTM) N/A
GM 89.98%
FCFM N/A
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 2.01
Debt/FCF N/A
Debt/EBITDA 9.16
Cap/Depr 41.57%
Cap/Sales 0.67%
Interest Coverage 0.58
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 2.6
Altman-Z -0.74
F-Score5
WACC9.67%
ROIC/WACC0.44
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%181.82%
EPS Next Y183.38%
EPS Next 2Y127.63%
EPS Next 3Y114.67%
EPS Next 5Y85.87%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%30.09%
Revenue Next Year20.92%
Revenue Next 2Y21.85%
Revenue Next 3Y22.2%
Revenue Next 5Y20.95%
EBIT growth 1Y144.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year229.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.95%
OCF growth 3YN/A
OCF growth 5YN/A